Spectral Molecular Imaging´s Chairman and CEO Presented at an Invited Talk at the International Microscopy Congress in Rio de Janeiro

BEVERLY HILLS, Calif., Sep 25, 2010 (BUSINESS WIRE) — Cascade Technologies Corp. announced today that Dr. Daniel L. Farkas, Chairman and CEO of Spectral Molecular Imaging (SMI), CSDT’s wholly-owned subsidiary, delivered a lecture at a major international congress in Rio de Janeiro, Brazil on September 23rd, 2010.

At the International Microscopy Congress, he lectured–by special invitation–in a session entitled Instrumentation and Techniques in Advanced Optical Microscopy. The congress brings together a worldwide group of several hundred scientists, and focuses on optical imaging at the interdisciplinary frontiers of nanotechnology, medicine, life sciences, energy conversion and environmental protection, for improved human outcomes.

Dr. Daniel L. Farkas. Photo: Spectral Molecular Imaging, Inc.

Dr. Farkas has entitled his talk Translational Microscopy: High resolution optical imaging for the clinic, to reflect the translational (bench to bedside) emphasis of the material to be covered, based on results from his group’s research. This work constitutes the basis for all SMI products, and reflects the company’s philosophy of applying advanced biophotonic technologies for addressing unmet needs in the clinical realm.

“It is very important for a young company such as ours,” said Dr. Farkas, “to participate in the worldwide dialogue of dedicated researchers who are seeking to develop new and improved ways to image disease for better diagnosis and treatment. Major international conferences such as these,” he explained, “are the best venue to learn about recent developments, and at the same time communicate our ideas and advances to a community that presents great collaborative opportunities for us.”

Dr. Farkas has been an active voice in international meetings through the years, having presented about 200 invited and plenary talks, and having organized and chaired 25 international conferences, mostly in biomedical optics. Within the past year, he lectured at the European Biophysics Congress in Genova, Italy; at the Biomedical Optics Society conference in San Francisco; at the Beckman Laser Institute and Medical Clinic at UC Irvine; at the Electrochemical Society Meeting in Vancouver (two talks); at the Association for Research in Vision and Ophthalmology conference in Ft. Lauderdale; at the International Brain Mapping and Intraoperative Surgical Planning Society congress (New Horizons track) in Bethesda; at the World Congress of Minimally Invasive Spine Surgery in Las Vegas; at the Surgical Navigation division of Medtronic Corporation and in the University of Southern California Physical Sciences in Oncology Center Seminar Series. These talks, and the invitations to present them, reflect the diversity and interdisciplinary nature of the applications enabled by the ground-breaking optical bioimaging that constitutes the core of SMI’s efforts, and the widespread interest, both scientific and clinical, that they elicit.

About Spectral Molecular Imaging

Spectral Molecular Imaging, Inc., a wholly-owned subsidiary of Cascade Technologies Corp, is a development-stage medical imaging device company, applying its proprietary hyperspectral-optical imaging technology–originally developed for satellite reconnaissance–to advance the early and accurate diagnoses of cancer and precancerous conditions. SMI is developing non-invasive, high-resolution optical imaging systems using its patented technology and other proprietary knowhow for improved clinical diagnostics, primarily in the field of cancer pathology, by identification and analysis of certain molecular, cellular, and tissue features via hyperspectral-imaging approaches. We expect to provide services related to our primary products, including software modules and maintenance services, and to develop optical diagnostic products that operate in conjunction with surgical and/or evaluation procedures in real time. We believe that our technology will enable early detection and more reliable diagnosis of various diseases, such as melanoma, Barrett’s esophagus (a condition caused by chronic acid reflux that can lead to esophageal cancer) and lung cancer. We expect that medical devices using or based on our developed technology can significantly improve long-term patient outcomes and may substantially reduce overall costs for the healthcare system. For more information, please visit www.spectralmi.com

Forward-Looking Statements
This news announcement contains or may contain certain “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, without limitation, statements regarding SMI’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects”, “may”, “could”, “would”, “should”, “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans” or similar expressions. Such forward-looking statements are subject to significant risks and uncertainties, including those detailed in filings made by Cascade Technologies Corp., SMI’s parent, with the Securities and Exchange Commission. Accordingly we caution our readers that actual results may differ materially from our beliefs or expectations due to economic, business, competitive, market and regulatory factors. We assume no obligation or undertaking to update any forward-looking statements to reflect any changes in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. You should, however, review additional disclosures we make in the reports filed with the Securities and Exchange Commission.

SOURCE: Spectral Molecular Imaging, Inc.

Spectral Molecular Imaging, Inc.
Daniel L. Farkas, Ph.D., 310-858-1670
farkas@opmol.com

Copyright Business Wire 2010

www.spectralmi.com